VETCELL
LIVE

Serial Number

79095162

Owner

ReCellerate, Inc.

Filing Date

Mar 16, 2011

Add to watchlist:

No watchlists yet
View on USPTO

VETCELL Trademark

Serial Number: 79095162 • Registration: 4239666

VETCELL is a trademark filed by ReCellerate, Inc. on March 16, 2011. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

ReCellerate, Inc. (7 trademarks)

PO Box 852
Middleburg, VA 201170852

Entity Type: 03

Quy Biosciences Ltd.

18 Tannery Yard, Witney Street

Entity Type: 99

Trademark Details

Filing Date

March 16, 2011

Registration Date

November 13, 2012

Published for Opposition

August 28, 2012

Cancellation Date

March 16, 2021

Goods & Services

Pharmaceutical and veterinary preparations for orthopaedic, ophthalmic, neurologic, oncologic and immunologic use; pharmaceutical and veterinary preparations for use in regenerative medicine for the treatment of orthopaedic, ophthalmic, neurologic, oncologic and immunologic damage, tendon and ligament damage and injuries, musculoskeletal damage and injuries; pharmaceuticals and veterinary preparations for the treatment of orthopaedic, ophthalmic, neurologic, oncologic and immunologic damage, tendon and ligament damage and injuries, musculoskeletal damage and injuries; chemical preparations adapted for pharmaceutical, medical and veterinary use for treatment of orthopaedic, ophthalmic, neurologic, oncologic and immunologic damage, tendon and ligament damage and injuries, musculoskeletal damage and injuries; differentiated cells, stem cells and cells derived there from for medical, veterinary or clinical use; stem cells for cellular therapeutics for medical, veterinary or clinical use; cryo-preserved stem cells; cell-derived preparations for medical, veterinary or clinical use; platelet rich plasma; growth factor preparations for injection for the treatment of orthopaedic, ophthalmic, neurologic, oncologic and immunologic damage, tendon and ligament damage and injuries, musculoskeletal damage and injuries; surgical implants comprising of living tissue, namely, bones and soft tissue, allogeneic bone graft material; medical plasters, wound dressings, medical dressings

Chemicals for use in the cryo-preservation of cells, differentiated cells, stem cells and cells derived therefrom; chemicals for use in scientific research relating to the isolation, insertion, positioning and maintenance of differentiated cells, stem cells and cells derived therefrom

Medical services; veterinary services: medical and veterinary services relating to the isolation,insertion, positioning, maintenance, and storage of differentiated cells, stem cells and cells derived therefrom, and cell-derived preparations, platelet rich plasma and growth factor injections; medical and veterinary consultancy services

Surgical, medical, and veterinary apparatus and instruments for orthopaedic, ophthalmic, neurologic, oncologic and immunologic use; medical and veterinary apparatus and instruments for cryo-preservation of stem cells; surgical, medical and veterinary apparatus and instruments for use in the treatment of orthopaedic, ophthalmic, neurologic, oncologic and immunologic damage and injuries, tendon and ligament damage and injuries, musculoskeletal damage and injuries; surgical, medical and veterinary apparatus for use in the isolation, insertion, positioning and maintenance, including storage, of differentiated cells, stem cells and cells derived therefrom, cell-derived products and regenerative technology; artificial allogeneic bone graft material; ceramic bone graft substitute

Scientific research and development services and design services for others in the field of orthopaedics, ophthalmics, neurology, oncology, immunology, regenerative medicine, differentiated cells, stem cells and cells derived there from, cellular and cell-derived therapeutics; veterinary and medical research services; scientific and industrial research in the field of orthopaedics, ophthalmics, neurology, oncology, immunology, regenerative medicine, differentiated cells, stem cells and cells derived there from, cellular and cell-derived therapeutics; scientific research and development services relating to regenerative medicine and technologies; scientific research and development relating to differentiated cells, stem cells and cells derived there from and cell-derived therapeutics; scientific research and development relating to cellular and cell-derived therapeutics; providing scientific and medical research information on pharmaceutical, medical and veterinary products and services through an on-line computer network

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Nov 7, 2021 DENC
DEATH OF INTERNATIONAL REGISTRATION
Nov 7, 2021 DETH
NEW REPRESENTATIVE AT IB RECEIVED
Feb 5, 2021 NREP
TOTAL INVALIDATION PROCESSED BY THE IB
Jan 5, 2019 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Dec 2, 2018 INTS
INVALIDATION PROCESSED
Dec 2, 2018 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Nov 20, 2018 INTR
CANCELLED SECTION 18-TOTAL
Mar 20, 2018 C18.
CANCELLATION TERMINATED NO. 999999
Mar 20, 2018 CANT
CANCELLATION GRANTED NO. 999999
Mar 20, 2018 CANG
CANCELLATION INSTITUTED NO. 999999
Oct 31, 2017 PETC
CHANGE OF OWNER RECEIVED FROM IB
May 31, 2015 CHLD
NEW REPRESENTATIVE AT IB RECEIVED
Jul 31, 2014 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 10, 2013 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 15, 2013 FICS
FINAL DISPOSITION PROCESSED
Feb 15, 2013 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 13, 2013 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 13, 2012 R.PR
NOTIFICATION PROCESSED BY IB
Sep 29, 2012 GPNX
PUBLISHED FOR OPPOSITION
Aug 28, 2012 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 8, 2012 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 8, 2012 OP2R
NOTICE OF PUBLICATION
Aug 8, 2012 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 25, 2012 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 24, 2012 CNSA
EXAMINERS AMENDMENT MAILED
Jul 11, 2012 CNEA
EXAMINER'S AMENDMENT ENTERED
Jul 11, 2012 XAEC
EXAMINERS AMENDMENT -WRITTEN
Jul 11, 2012 CNEA
AMENDMENT FROM APPLICANT ENTERED
Jun 30, 2012 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 30, 2012 CRFA
PAPER RECEIVED
Jun 20, 2012 MAIL
FINAL REFUSAL MAILED
Jan 11, 2012 CNFR
FINAL REFUSAL WRITTEN
Jan 10, 2012 CNFR
AMENDMENT FROM APPLICANT ENTERED
Jan 5, 2012 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 5, 2012 CRFA
ASSIGNED TO LIE
Dec 20, 2011 ALIE
PAPER RECEIVED
Dec 16, 2011 MAIL
REFUSAL PROCESSED BY IB
Aug 6, 2011 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 17, 2011 RFCS
REFUSAL PROCESSED BY MPU
Jun 17, 2011 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 17, 2011 RFCR
NON-FINAL ACTION WRITTEN
Jun 16, 2011 CNRT
ASSIGNED TO EXAMINER
Jun 15, 2011 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 19, 2011 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 15, 2011 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 14, 2011 REPR